Company Description
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases.
The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren’s Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and α7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor.
The company is headquartered in Palo Alto, California.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Lloyd Jordan |
Contact Details
Address: Building 4, Suite 200 Palo Alto, California 94306 United States | |
| Phone | 650 507 0669 |
| Website | 180lifesciences.com |
Stock Details
| Ticker Symbol | ATNF |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001690080 |
| CUSIP Number | 68236V104 |
| ISIN Number | US68236V3024 |
| Employer ID | 81-3832378 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sir Marc Feldmann Ph.D. | Co-Founder |
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder and Director |
| Prof. Jagdeep Nanchahal M.D., Ph.D. | Co-Founder and Chairman of Clinical Advisory Board |
| Jason Assad | Director of IR |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | ARS | Filing |
| Nov 12, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 12, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 29, 2024 | PRE 14A | Other preliminary proxy statements |
| Oct 29, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 8-K | Current Report |